National Institute of Diabetes and Digestive and Kidney Diseases; Cancellation of Meeting, 32670 [2013-12883]
Download as PDF
<![CDATA[
32670
Federal Register / Vol. 78, No. 105 / Friday, May 31, 2013 / Notices
• Complicated Urinary Tract
Infection (draft issued February 23,
2012); 2
• Uncomplicated Gonorrhea;
• Complicated Intra-Abdominal
Infection (draft issued September 28,
2012); 3
• Diabetic Foot Infection; and
• Hospital-Acquired and VentilatorAssociated Bacterial Pneumonia (draft
issued November 26, 2010).4
IV. Emerging Resistance to
Antibacterial Drugs
In addition to facilitating antibacterial
drug development, the task force
recognizes the need to address the issue
of emerging drug resistance. The public
health need caused by the lack of a
robust pipeline is further compounded
by the diminishing effectiveness of
currently available antibacterial drugs
due to emerging drug resistance.
Therefore, we are seeking comment on
strategies to preserve the utility of
antibacterial drugs.
V. Categories for Public Comment
We request the following information
from the public:
• Novel study designs to expedite the
development of new antibacterial drugs;
• Comments on our prioritized list of
proposed draft or final guidance
development; and
• Potential strategies intended to slow
the rate of emerging drug resistance.
When responding to this notice,
please include the category or categories
that your response addresses.
tkelley on DSK3SPTVN1PROD with NOTICES
VI. Comments
Interested persons may submit either
electronic comments to https://
www.regulations.gov or written
comments regarding this document to
the Division of Dockets Management
(see ADDRESSES). It is only necessary to
send one set of comments. Identify
comments with the docket number
found in brackets in the heading of this
document. When responding, include
the category or categories that your
response addresses as listed in section
V of this document. Received comments
may be seen in the Division of Dockets
2 Complicated Urinary Tract Infection Draft
Guidance available at https://www.fda.gov/
downloads/Drugs/
GuidanceComplianceRegulatoryInformation/
Guidances/UCM070981.pdf.
3 Complicated Intra-Abdominal Infection Draft
Guidance available at https://www.fda.gov/
downloads/Drugs/
GuidanceComplianceRegulatoryInformation/
Guidances/UCM321390.pdf.
4 Hospital Acquired and Ventilator Associated
Pneumonia Draft Guidance available at https://
www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/
Guidances/UCM234907.pdf.
VerDate Mar<15>2010
17:40 May 30, 2013
Jkt 229001
Management between 9 a.m. and 4 p.m.,
Monday through Friday, and will be
posted to the docket at https://
www.regulations.gov.
Dated: May 24, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–12925 Filed 5–30–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases;
Cancellation of Meeting
Notice is hereby given of the
cancellation of the National Institute of
Diabetes and Digestive and Kidney
Diseases Special Emphasis Panel, June
13, 2013, 8:00 a.m. to June 13, 2013,
4:00 p.m., St. Gregory Hotel, 2033 M
Street NW., Washington, DC, 20036
which was published in the Federal
Register on April 10, 2013, 78 FR 21381.
This meeting is being cancelled due to
a scheduling conflict.
Dated: May 24, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–12883 Filed 5–30–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cognition and Perception.
Date: June 19, 2013.
Time: 2:00 p.m. to 3:30 p.m.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Jane A DoussardRoosevelt, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 3184, MSC 7848, Bethesda, MD 20892,
(301) 435–4445, doussarj@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Societal and Ethical Issues in
Research.
Date: June 20, 2013.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Agenda: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Lisa Steele, Ph.D.,
Scientific Review Officer, PSE IRG, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, 301–594–
6594, steeleln@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 12–
251: Review of B/START Applications.
Date: June 21, 2013.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Jose H Guerrier, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1137, guerriej@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA–RM–
12–018: NIH Director’s Early Independence
Awards Review.
Date: June 24–25, 2013.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz Carlton Hotel, 1150 22nd Street,
NW., Washington, DC 20037.
Contact Person: Weijia Ni, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3184, MSC 7848, Bethesda, MD
20892, (301) 237–9918, niw@csr.nih.gov.
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group;
Therapeutic Approaches to Genetic Diseases
Study Section.
Date: June 26, 2013.
Time: 8:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Elaine Sierra-Rivera, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6184,
MSC 7804, Bethesda, MD 20892, 301–435–
1779, riverase@csr.nih.gov.
E:\FR\FM\31MYN1.SGM
31MYN1
]]>Agencies
[Federal Register Volume 78, Number 105 (Friday, May 31, 2013)]
[Notices]
[Page 32670]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-12883]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Cancellation of Meeting
Notice is hereby given of the cancellation of the National
Institute of Diabetes and Digestive and Kidney Diseases Special
Emphasis Panel, June 13, 2013, 8:00 a.m. to June 13, 2013, 4:00 p.m.,
St. Gregory Hotel, 2033 M Street NW., Washington, DC, 20036 which was
published in the Federal Register on April 10, 2013, 78 FR 21381.
This meeting is being cancelled due to a scheduling conflict.
Dated: May 24, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-12883 Filed 5-30-13; 8:45 am]
BILLING CODE 4140-01-P
